Archive

Durata Therapeutics Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI
December 11, 2012


Intarcia Therapeutics Secures Landmark $210 Million Financing to Fund Its Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
November 15, 2012


Spiracur Awarded Two HCPCS Codes for Wound Care Treatment
November 15, 2012


Transcept Pharmaceuticals Reports Third Quarter 2012 Financial Results
November 12, 2012


Durata Therapeutics Reports Third Quarter 2012 Financial and Corporate Results
November 9, 2012


NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
November 8, 2012


Synageva BioPharma Reports Third Quarter 2012 Financial Results
November 6, 2012


MEI Pharma Announces $27.5 Million Private Placement
November 5, 2012


FDA Designates Durata Therapeutics’ Dalbavancin a Qualified Infectious Disease Product (QIDP)
November 5, 2012


Advanced Cell Diagnostics Completes $12 Million Series B Financing
November 1, 2012


Epocrates Announces Third Quarter 2012 Results
October 30, 2012


Durata Therapeutics Completes Target Enrollment in Phase 3 DISCOVER 2 Clinical Trial Comparing Dalbavancin to Vancomycin and Linezolid in ABSSSI Patients
October 25, 2012


Pearl Therapeutics Successfully Completes Phase 2 Program; Identifies Optimal Dose of PT003 and its Components for Phase 3
October 24, 2012


Direct Flow Medical® Transcatheter Aortic Valve System Shown To Virtually Eliminate Aortic Regurgitation With No Vascular Complications In DISCOVER CE Mark Trial
October 23, 2012


Array BioPharma To Report Financial Results For The First Quarter Of Fiscal 2013
October 23, 2012


New York Digital Health Accelerator Reveals Inaugural Class
October 15, 2012


Intercept Pharmaceuticals Announces Pricing of Initial Public Offering
October 11, 2012


IlluminOss Medical Secures $28 Million Series C Financing for Minimally Invasive Bone Fracture Repair
September 27, 2012


Karus Therapeutics Secures Series B Financing from a Syndicate of Leading VC Investors
September 6, 2012


Spiracur Awarded NHS Supply Chain Framework Agreement and Drug Tariff Approval in England and Wales for SNaP Wound Care System
September 5, 2012


Durata Therapeutics, Inc. Reports Second Quarter 2012 Financial and Corporate Results
September 4, 2012


Durata Therapeutics Announces Five Abstracts Concerning Dalbavancin and Management of abSSTI at ICAAC 2012
August 29, 2012


Relypsa Announces $80 Million Private Financing Transaction
August 15, 2012


Transcept Pharmaceuticals Reports Second Quarter 2012 Financial Results
August 13, 2012


Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
August 13, 2012


NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
August 8, 2012


Durata Therapeutics Prices Initial Public Offering
July 19, 2012


Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
June 6, 2012


Transcept Pharmaceuticals Reports First Quarter 2012 Financial Results
May 14, 2012


Synageva BioPharma Reports First Quarter 2012 Financial Results
May. 9, 2012


NxStage Reports Revenue for the First Quarter of Fiscal 2012; Advances Growth Strategy
May 8, 2012


Spiracur Announces Final Results from Multi-Center Randomized Controlled Clinical Trial
May 8, 2012


Epocrates Announces First Quarter 2012 Results
May 1, 2012


Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2012
April 30, 2012


Direct Flow Medical® Announces the Appointment of Chief Medical Officer, Charles Davidson, MD
April 30, 2012


Tioga Pharmaceuticals, Inc. Raises $10 Million to Advance Phase 3 Clinical Development of Asimadoline in Irritable Bowel Syndrome
April 12, 2012


Synageva BioPharma and Mitsubishi Tanabe Pharma Corporation Expand Development Collaboration with Second Program
April 2, 2012


Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
April 02, 2012


Bausch + Lomb to Acquire ISTA Pharmaceuticals
March 26, 2012


Synageva BioPharma Reports 2011 Full Year Financial Results
March 15, 2012


Transcept Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
March 14, 2012


Bubble Year IRRs A Drag On SFERS Venture Portfolio: Slideshow
March 5, 2012


Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-modified Dextromethorphan for Disorders of the Nervous System
February 29, 2012


Epocrates Streamlines Strategic Focus and Reports Fourth Quarter and Full Year 2011 Results
February 28, 2012


AccessClosure, Inc. Launches MynxGrip™ Vascular Closure Device
February 27, 2012


Truveris Attracts $10 Million in New Capital, Contains Drug Benefit Costs
February 23, 2012


ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results
February 23, 2012


Biogen Idec to Acquire Stromedix
February 14, 2012


NxStage® to Report Fourth Quarter and Full Year 2011 Financial Results
January 20, 2012


Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
January 6, 2012


Synageva Biopharma Announces Pricing Of Public Offering Of Common Stock
January 5, 2012


Transcept Pharmaceuticals Announces FDA Approval of Intermezzo® (zolpidem tartrate sublingual tablet) C-IV For Use as Needed for the Treatment of Insomnia When a Middle-of-the-Night Awakening is Followed by Difficulty Returning to Sleep
November 23, 2011


Transcept Pharmaceuticals Reports Third Quarter 2011 Financial Results
November 10, 2011


Synageva BioPharma Announces Completion of Merger with Trimeris
November 3, 2011


NxStage Reports Record Third Quarter 2011 Financial Results and Raises Revenue Guidance For 2011
November 3, 2011


ISTA Pharmaceuticals Reports Third Quarter 2011 Financial Results
November 1, 2011


Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
August 30, 2011


Epocrates Reports 2011 Second Quarter Financial Results and Updated 2011 Guidance
August 9, 2011


Transcept Pharmaceuticals to Report Second Quarter 2011 Financial Results, and Host Conference Call on August 11, 2011
August 4, 2011


NxStage Reports Record Second Quarter 2011 Financial Results and Raises Revenue Guidance for 2011
August 3, 2011


ISTA Pharmaceuticals Reports Second Quarter 2011 Financial Results
July 28, 2011


Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
July 19, 2011


Concert Pharmaceuticals Announces Milestone Achievement in GlaxoSmithKline Collaboration
June 20 , 2011


ReShape Medical Announces Results Of Phase 1 U.S. Clinical Study For Weight Loss
June 17, 2011


Pearl Therapeutics Advances its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
June 16, 2011


Synageva Biopharma And Trimeris Announce Merger Agreement
June 13, 2011


Durata Therapeutics Announces Dalbavancin Production Capabilities and Signing of Global Manufacturing Agreement
June 6, 2011


FDA Grants Fast Track Designation to Tioga Pharmaceuticals’ Asimadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
June 1, 2011


Prometheus Announces Agreement to be Acquired by Nestlé Health Science
May 24, 2011


Takeda to Acquire Nycomed
May 19, 2011


Pearl Therapeutics’ Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
May 18, 2011


Transcept Pharmaceuticals Reports First Quarter 2011 Financial Results
May 16, 2011


Neuronetics, Inc. Raises $30 Million in Series E Financing
May 16, 2011


New Trial Data Confirm Clinical Effectiveness and Good Adherence Rates with NeuroStar TMS Therapy in Patients with Major Depressive Disorder Treated in a Real World Practice Setting
May 14, 2011


Affymax® Reports First Quarter 2011 Financial Results
May 11, 2011


iRhythm Technologies, Inc. Raises $15 Million Series C Equity Round
May 4, 2011


ISTA Pharmaceuticals Reports First Quarter 2011 Financial Results
May 4, 2011


Epocrates to Report 2011 First Quarter Financial Results and Host Conference Call on May 10, 2011
April 26, 2011


Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
April 25, 2011


NxStage® to Report First Quarter Fiscal 2011 Financial Results
April 12, 2011


Convergence Pharmaceuticals Announces Phase I Trial Start of CNV2197944 for Chronic Pain
April 12, 2011


Concert Pharmaceuticals Advances Novel Chronic Kidney Disease Treatment, CTP-499, in Phase 1 Clinical Study
March 29, 2011


Epocrates Reports 2010 Fourth Quarter and Full-Year Financial Results and Provides 2011 Outlook
March 29, 2011


Transcept Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
March 16, 2011


Affymax® Reports Year End 2010 Financial Results
March 10, 2011


Nycomed’s novel COPD therapy roflumilast receives FDA approval
March 1, 2011


HHS awards contracts to develop new flu vaccine technology
February 28, 2011


ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
February 23, 2011


NxStage® Reports Fourth Quarter and Full-Year 2010 Financial Results; Revenue Growth Exceeds Company Guidance
February 17, 2011


Versartis Completes $21 Million Series B Financing
February 16, 2011


Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
February 14, 2011


Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
February 10, 2011


Epocrates, Inc. Announces Pricing of Initial Public Offering
February 2, 2011


Transcept Pharmaceuticals Resubmits Intermezzo® New Drug Application for the Treatment of Middle of the Night Awakenings
January 18, 2011


Hologic Acquires Interlace Medical
January 7, 2011


Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
December 14, 2010


ISTA Pharmaceuticals Initiates Phase 2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
December 14, 2010


Pearl Therapeutics’ PT003 Combination Therapy for COPD Demonstrates Superior Bronchodilation Compared to Spiriva® and Foradil® in Randomized Phase 2b Study
December 1, 2010


ISTA Pharmaceuticals Granted Three-Year Market Exclusivity for BROMDAY™
November 17, 2010


Pearl Therapeutics Raises $69 Million Series C Financing
October 19, 2010


Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
October 19, 2010


ISTA Pharmaceuticals Receives FDA Approval for BROMDAY™
October 16, 2010


World Heart Corp. to Raise $25.3 Million in Private Placement
October 14, 2010


Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
October 12, 2010


ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
October 06, 2010


New Leaf Venture Partners Invests in $35.4 (GBP 22.4) Million Series A Financing of Convergence Pharmaceuticals
October 5, 2010


BioRelix Enters Antibacterial Collaboration with Merck
October 4, 2010


New Randomized Controlled Trial Supports Efficacy And Safety Of Spiracur SNaP Wound Care System
September 27, 2010


First European Filing for Marketing Approval of Osteoporosis Drug
September 21, 2010


Daxas® (roflumilast) data analysis shows reduction in harmful lung attacks
September 19, 2010


Relypsa Raises $70 Million in Series B Financing
September 13, 2010


Neuronetics selected by World Economic Forum as 2011 Technology Pioneer
September 1, 2010


Afferent Pharmaceuticals Presents Data Supporting Use of P2X3 Antagonists in Reducing Bone Cancer Pain
September 1, 2010


Afferent Pharmaceuticals Announces Data Supporting Potential Utility of Proprietary P2X3 Antagonists in Regulating Bladder Reflexes
August 25, 2010


Oxford Immunotec announces US FDA approval of PMA supplement for the use of the T-Cell Xtend® reagent
August 11, 2010


WorldHeart Receives FDA Approval to Add Clinical Sites in Levacor™ VAD Bridge-to-Transplant Study
July 27, 2010


Epocrates, Inc. Files Registration Statement for Proposed Initial Public Offering
July 16, 2010


Synageva Biopharma Receives Orphan Drug Designation for SBC-102 for Lysosomal Acid Lipase Deficiency
July 7, 2010


ISTA Pharmaceuticals Announces Phase III Results For Once-Daily Topical Xibrom™ 0.09%
July 1, 2010


Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
June 28, 2010


Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
June 28, 2010


Olympus to Acquire Spiration, Inc., a U.S. Pulmonary Device Company, as a Consolidated Subsidiary
June 25, 2010


Tioga Pharmaceuticals Begins Phase 3 Trial of Asimadoline in Irritable Bowel Syndrome
June 3, 2010


Sandoz completes acquisition of Oriel Therapeutics, strengthening potential for global leadership in respiratory
June 3, 2010


Spiration Announces Positive Results of European Study Evaluating Safety and Effectiveness of Bronchial Valve Treatment for Severe Emphysema
May 19, 2010


Altura Medical Completes $20 Million Round of Financing
May 18, 2010


Pearl Therapeutics’ Data for its Combination Bronchodilator Product, PT003, Support the Potential for Improvement in the Treatment of Patients with COPD
May 18, 2010


Nycomed and Forest Laboratories receive complete FDA response letter for Roflumilast – no additional patient trials were requested
May 17, 2010


Prometheus Unveils Novel Approach for Predicting Risk of Disease Progression in Patients with Crohn’s Disease
May 3, 2010


Oxford Immunotec Closes Second Tranche of $26 Million Series D Financing Led by New Leaf Venture Partners
April 30, 2010


GE Healthcare and Nycomed to Form Joint Venture to Sell, Market and Distribute Medical Diagnostic Contrast Agents in Russia and CIS
April 27, 2010


VaxInnate’s VAX125 Seasonal Flu Vaccine Shown Safe and Highly Immunogenic in Phase II Study of Elderly Subjects
April 27, 2010


Nycomed and Merck & Co., Inc., Announce Commercialization Agreements for Daxas® in Europe and Canada
April 26, 2010


Nycomed’s Novel Anti-Inflammatory Therapy Daxas® (Roflumilast) Recommended for Approval in the European Union for Patients with COPD
April 23, 2010


Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products targeting asthma and COPD
April 19, 2010


WorldHeart Announces Levacor VAD Implant at Inova Fairfax Hospital, Virginia
April 13, 2010


NxStage® Expands Streamline® Blood Tubing Set and MasterGuard® Needle Supply Agreement with Renal Advantage Inc.
April 12, 2010


Nycomed and Baxter receive FDA approval for TachoSil®, an adjunct to haemostasis in cardiovascular surgery
April 6, 2010


Tioga Pharmaceuticals Receives Special Protocol Assessment Agreement from FDA for Phase 3 Trials of Asimadoline in Irritable Bowel Syndrome
April 5, 2010


Concert Pharmaceuticals Granted Patent for Deuterated Paroxetine Compounds, Including CTP-347
March 31 , 2010


Interlace Medical Initiates Clinical Trial of Myosuretm for Office-Based Treatment of Submucosal Fibroids
March 30, 2010


Pearl Therapeutics Announces Positive Results From Phase 1 Trial of Pt003, a Bronchodilator Combination Therapeutic for Chronic Obstructive Pulmonary Disease, and Initiation of Phase 2b Trial
March 29, 2010


Transcept Pharmaceuticals Updates Plan for Intermezzo® NDA Resubmission Following Teleconference With the FDA
March 24, 2010


Oxford Immunotec announces contract with Scancell Ltd to measure T cell
March 23, 2010


Transcept Pharmaceuticals Granted Second U.S. Patent Covering Intermezzo® Formulation
March 23, 2010


WorldHeart Announces Levacor VAD Implant at the University of Utah
March 23, 2010


Prometheus and Bayer Schering Pharma to Apply Novel Diagnostic Platform to Oncology Therapeutic Candidates
March 17, 2010


Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide™ in Japan
March 10, 2010


ISTA Pharmaceuticals Receives Action Date for FDA Review of Once-Daily XiDay™
March 8, 2010


Auxilium Announces Availability of XIAFLEX™ for the Treatment of Dupuytren's Contracture
March 8, 2010


NxStage Announces New FREEDOM Data Showing the Positive Impact of its Daily Home Hemodialysis Therapy on Sleep Quality and Restless Legs Syndrome
March 8, 2010


ReShape Medical Announces Initiation of U.S. Clinical Study for Weight Loss
March 3, 2010


NxStage® and Dirinco Sign Distribution Agreement For System One™ in the Netherlands
March 2, 2010


Tioga Pharmaceuticals, Inc. Raises $18 Million to Fund Phase 3 Clinical Trial in Irritable Bowel Syndrome
February 17, 2010


Transcept Pharmaceuticals Granted First U.S. Patent Covering Intermezzo® Formulation
February 9, 2010


Auxilium Announces U.S. Food and Drug Administration Approval for XIAFLEX™ for the Treatment of Dupuytren's Contracture
February 3, 2010


NxStage® and Nordic Medcom Sign Distribution Agreement for the System One™
February 3, 2010


Pearl Therapeutics Raises $15 Million to Advance PT003, LAMA/LABA Combination Bronchodilator for COPD, into Phase 2b Study
February 1, 2010


World Heart Corp. Completes $7.3 Million Private Placement
January 26, 2010


Prometheus Acquires Exclusive Rights to PROLEUKIN® (aldesleukin) in the U.S.
January 26, 2010


Labcyte Expands Acoustic Dispensing and Launches Into New Markets
January 26, 2010


Affymax Completes Treatment and Last Patient Follow-up in Phase 3 Program for Investigational Drug, Hematide™, to Treat Anemia in Chronic Renal Failure
January 25, 2010


Pfizer and Auxilium Announce Commencement of European Regulatory Review of XIAFLEXTM for the Treatment of Dupuytren's Contracture
January 21, 2010


WorldHeart Announces First U.S. Implant of Levacor™ VAD Implant at INTEGRIS in Oklahoma City
January 19, 2010


ISTA Pharmaceuticals announces trial results for topical Xibrom 0.09%
January 11, 2010


WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor™ VAD
January 8, 2010


Tolerx Completes Enrollment in DEFEND-1, a Phase 3 Type 1 Diabetes Study with Otelixizumab
January 7, 2010


Sopherion Therapeutics Receives FDA Fast Track Designation for Myocet in Metastatic Breast Cancer
January 7, 2010


Prometheus Completes $260 Million Financing
January 7, 2010


Pearl Therapeutics Announces Positive Results from Phase 2a Trial of Glycopyrrolate Inhalation Aerosol in Chronic Obstructive Pulmonary Disease
January 6, 2010


Pearl Therapeutics Announces Positive Results from Phase 2a Trial of Formoterol Inhalation Aerosol in Chronic Obstructive Pulmonary Disease
January 4, 2010


Newly Formed Durata Therapeutics Acquires Pfizer’s Vicuron Subsidiary
December 21, 2009


ISTA Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Once-Daily XiDay™
December 17, 2009


Auxilium Announces Top Line Phase IIb XIAFLEX™ Peyronie's Results
December 16, 2009


Roche Licenses First-in-Class Treatments for Chronic Pain to Afferent Pharmaceuticals; Afferent Secures $23 Million in Series A Financing
December 16, 2009


Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo®
December 14, 2009


WuXi PharmaTech Selects Labcyte POD™ 810 Platform for High-Throughput Screening
December 07, 2009


Affymax Announces Close of Common Stock Offering and Exercise of Underwriters' Overallotment Option
November 24, 2009


WorldHeart Signs Agreements for Next-Generation Minimally Invasive Blood Pump
November 17, 2009


NeuroStar TMS Therapy® Receives Prestigious Popular Science Award
November 12, 2009


3M Licenses Vaccine Adjuvants to VaxInnate
November 9, 2009


Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of CTP-518, Protease Inhibitor for Treatment of HIV
November 9, 2009


Transcept Pharmaceuticals Receives Notice of Allowance for U.S. Patent Application on Intermezzo®
November 4, 2009


Affymax and Takeda Announce Preliminary Phase 2 Data Demonstrated That Hematide™ Increased Hemoglobin in Dialysis Patients
October 30, 2009


Epocrates Celebrates 10 Years of Innovation
October 29, 2009


FDA Clears Interlace Medical’s MyoSure™ Hysteroscopic Tissue Removal System for The Treatment of Submucosal Fibroids
October 28th, 2009


Ligand to Acquire Metabasis for Cash and Contingent Value Rights
October 27, 2009


NxStage® Reports Significant Interim FREEDOM Study Results
October 27, 2009


Synageva Biopharma Announces Completion of $45 Million Financing with New $12 Million Investment, Addition of New Leaf Venture Partners to Investor Group, and Expansion of Senior Leadership Team
October 20, 2009


Prometheus Awarded Patent Related to Genetic Testing for Inflammatory Bowel Disease
October 20, 2009


WorldHeart Receives IRB Approval at First Center in the Levacor™ VAD BTT Clinical Trial Center On-Site Training Completed
October 15, 2009


Prometheus Launches ProOncDx Cancer Diagnostics
October 15, 2009


Relypsa Initiates Phase 2b Clinical Trial of RLY5016 for the Prevention of Hyperkalemia in Heart Failure Patients
October 7, 2009


Direct Flow Medical Presents Twelve Month Clinical Results with their Percutaneous Aortic Valve System at TCT
October 5, 2009


Boston Business Journal Names NxStage® Medical Third Fastest Growing Company in Massachusetts
October 1, 2009


Cyberonics Announces Epilepsy Technology Collaborations
October 1, 2009


Labcyte Signs Bioscreen Instruments as Exclusive Distributor in India
September 23, 2009


Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
September 17, 2009


U.S. Food and Drug Administration's Arthritis Advisory Committee Votes Unanimously 12-0 to Recommend Approval of XIAFLEX™ for Dupuytren's Contracture
September 16, 2009


Concert Pharmaceuticals Presents Clinical Results Demonstrating Reduced Drug-Drug Interactions with a Deuterium-Modified Compound
September 14, 2009


NxStage® Announces Streamline® Blood Tubing Set Supply Agreement Between Medisystems® and Reliant Renal Care
September 14, 2009


Affymax Provides Phase 3 Program Update for Investigational Drug, Hematide™, to Treat Anemia in Chronic Renal Failure
September 9, 2009


Prometheus Announces Co-Pay Assistance Savings Program For LOTRONEX® (Alosteron Hcl) Tablets
September 9, 2009


ISTA Pharmaceuticals' Bepreve™ Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
September 8, 2009


ISTA Pharmaceuticals Announces Preliminary Results of T-Pred Studies
September 8, 2009


XIAFLEX™ CORD I Study Published in New England Journal of Medicine
September 2, 2009


Abbott to Acquire Visiogen, Expanding Vision Care Portfolio
September 2, 2009


New Leaf Venture Partners Leads $30 Million Financing in Neuronetics
September 2, 2009


Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co. Announce Agreement to Develop and Commercialize Asimadoline in Japan
September 1, 2009


Aureon Laboratories Announces Appointment of New CEO
August 25, 2009


ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom™ 0.09%
August 25, 2009


WorldHeart Receives US Clinical Study Approval for the Levacor™ VAD
August 20, 2009


Labcyte Awarded Second Japanese Patent
August 18, 2009


XDx Completes $14.4 Million Series G Financing XDx Poised to Achieve Break-Even in 2010
August 5, 2009


Auxilium Pharmaceuticals, Inc. Secures $30 Million Revolving Credit Line With Silicon Valley Bank
August 5, 2009


Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo® in the United States
August 2, 2009


U.S. Food and Drug Administration's Arthritis Advisory Committee Confirms Date to Review XIAFLEX™ for the Treatment of Dupuytren's Contracture
July 31, 2009


Affymax Announces Data Monitoring Committee Review of Phase 3 Hematide Program
July 20, 2009


Prometheus Launches MyCeliacID™, The First Do It Yourself, Saliva-Based Genetic Test Dedicated To Celiac Disease
June 29, 2009


U.S. Food and Drug Administration's Arthritis Advisory Committee Sets Tentative Date to Review XIAFLEX™ for the Treatment of Dupuytren's Contracture
June 18, 2009


Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo®
June 11, 2009


Metabasis Therapeutics Announces That Its Collaborator Merck & Co., Inc. Has Selected a Lead AMPK Activator for Late Preclinical Development and Has Agreed to Make a One-Time Payment for All Remaining Financial Obligations
June 10, 2009


Metabasis Therapeutics Receives a Development Event Payment from Roche and Notification That Roche Plans to Advance MB11362 into Development for the Treatment of Hepatitis C
June 5, 2009


Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs
June 2, 2009


Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
June 2, 2009


NxStage Extends Supply Agreement with B. Braun Medical Inc. to Include Streamline(R) Technology
June 1, 2009


Affymax® Reports Phase 2 Clinical Trial Data Supporting Hemoglobin Increases with Once-Per-Month Hematide™ Regardless of Patient Baseline Renal Function
May 26, 2009


Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
May 21, 2009


NxStage Announces Strategic Business Alliance with Asahi Kasei Kuraray Medical
May 18, 2009


VaxInnate Corporation Closes $30 Million Round of Financing; Wellcome Trust Leads Round
May 6, 2009


XIAFLEX™ for the Treatment of Dupuytren's Contracture Receives Priority Review from the U.S. Food and Drug Administration
April 28, 2009


Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
April 13, 2009


Prometheus Highlights Record Performance in 2008
March 24, 2009


NxStage Announces Credit Facility Amendment
March 16, 2009


Prometheus Receives New York State Approval for Prometheus® IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome
March 16, 2009


Auxilium Submits Biologics License Application for XIAFLEX™ for the Treatment of Dupuytren's Contracture to the U.S. Food and Drug Administration
March 02, 2009


IlluminOss Medical Receives ISO 13485 Certification
February 20, 2009


IlluminOss Announces First Human Case Utilizing Its Innovative Photodynamic Bone Stabilization System Technology
February 19, 2009


Affymax Announces $42 Million Private Placement
February 17, 2009


Auxilium Pharmaceuticals, Inc. Completes Enrollment in Phase IIb Clinical Trial of XIAFLEX™ in Peyronie's Disease
February 2, 2009


Novacea Stockholders Approve Merger With Transcept
January 27, 2009


ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
January 22, 2009


WorldHeart Submits IDE Application for a Pivotal Bridge-to-Transplant Study of the Levacor™ VAD
January 8, 2009


Auxilium Pharmaceuticals, Inc. and Pfizer Enter Agreement to Develop and Commercialize XIAFLEX™ in Europe
December 17, 2008


Transcept Announces FDA Acceptance for Review of New Drug Application for Intermezzo®
December 16, 2008


Epocrates Offers International Market Research Panel
November 20, 2008


Affymax Announces Another Favorable Data Monitoring Committee Review of Phase 3 Hematide Program
November 20, 2008


Epocrates Survey Identifies Trends in Online Resource Use Among Physicians
November 18, 2008


Affymax Completes Enrollment in Phase 3 Program for Hematide in Chronic Renal Failure with Completion of Enrollment in EMERALD 2, the Final of Four Phase 3 Clinical Trials of Hematide™
November 17, 2008


ISTA Pharmaceuticals Ranked Number Twelve in Deloitte's Technology Fast 500 Program for Fastest Growing Companies in North America
November 13, 2008


ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve™
November 13, 2008


Fifty Thousand Physicians Choose Epocrates iPhone App
November 6, 2008


Affymax Announces New Data Presented on the Long-Term Safety and Effectiveness of Hematide™ to Treat Anemia in Chronic Renal Failure Patients with Monthly Dosing
November 6, 2008


Affymax Completes Enrollment in PEARL 2, the Second of Four Phase 3 Clinical Trials of Hematide to Treat Anemia in Chronic Renal Failure Patients
November 3, 2008


Transcept Submits NDA for Intermezzo® for Treatment of Middle-of-the-Night Awakenings
October 1, 2008


ISTA Pharmaceuticals Receives $65 Million Funding Commitment
September 26, 2008


Concert Pharmaceuticals Presents Preclinical Results Supporting Co-Administration of CTP-347 and Tamoxifen
September 25, 2008


One Million Epocrates MobileCME Courses Completed
September 25, 2008


Oriel Therapeutics Appoints Richard Fuller as Chief Executive Officer
September 23, 2008


Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX™ Phase IIb Study for Peyronie's Disease
September 17, 2008


Apple iPhone Becomes a Patient Safety Device with Epocrates
September 15, 2008


Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
September 9, 2008


Novacea, Inc. and Transcept Pharmaceuticals, Inc. Sign Merger Agreement
September 2, 2008


Patent Issued Related to Prometheus Proprietary Test; CBir1 Antigen Test Included in Diagnostic for Inflammatory Bowel Disease
August 21, 2008


Affymax Announces Favorable Data Monitoring Committee Review of Phase 3 Hematide Program
August 7, 2008


WorldHeart Closes US$30 Million in Financing
August 1, 2008


Angiotech To Establish Separate Operating And Royalty Businesses
July 7, 2008


Pearl Therapeutics Closes $18 Million Financing
July 2, 2008


Tioga Pharmaceuticals’ Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
May 20, 2008


Aureon Laboratories Introduces Prostate Px® , First Biopsy-Based Test to Predict Prostate Cancer Disease Progression and Recurrence
May 19, 2008


Affymax and Takeda Announce Long-Term Hematide Safety and Effectiveness Data from Phase 2 Clinical Trials in Chronic Kidney Disease Patients with Anemia
May 12, 2008


NxStage Announces Supply Agreement With Kawasumi Laboratories for Blood Tubing Sets
May 7, 2008


ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
April 30, 2008


CoNCERT Pharmaceuticals Raises $37 Million in Series C Financing
April 30, 2008


Stromedix Raises $25 Million Series B for Fibrosis Programs, Begins Clinical Trial
April 21, 2008


IlluminOss Medical Completes $11 Million Series B Financing
April 18, 2008


Metabasis Therapeutics Raises Approximately $10 Million Through a Warrant Exchange and Concurrent Private Placement
April 16, 2008


Apple Announces iPhone 2.0 Software Beta
March 6, 2008


Artisan Pharma's Lead Product, ART-123, Approved in Japan
February 22, 2008


ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom™ Combination Therapy with Lucentis®
February 22, 2008


SGX Initiates Phase I Trials for SGX523
January 16, 2008


Epocrates Inc. Announces Strategic Investment by Goldman Sachs
January 7, 2008


NxStage Medical Announces Needle Supply Agreement with DaVita
January 7, 2008


Aspreva's Plan of Arrangement with Galenica Completed
January 3, 2008


ISTA Pharmaceuticals Submits New Drug Application for Xibrom™ QD (once-daily)
December 20, 2007


Kalypsys Initiates Phase IIa Clinical Trial of Topical iNOS Inhibitor
December 18, 2007


Auxilium Pharmaceuticals, Inc. Completes Enrollment in Two Phase III Clinical Trials of XIAFLEX™ for Dupuytren's Contracture
December 17, 2007


SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
December 3, 2007


Prometheus Licenses Colal-Pred® From Alizyme
November 29, 2007


NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital
November 21, 2007


SGX Pharmaceuticals Announces $25 Million Private Placement
November 20, 2007


Prescription for Success: Epocrates for BlackBerry -
Popular Medical Software Now Available for BlackBerry Smartphones

November 14, 2007


BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
November 13, 2007


ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom™ QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
November 12, 2007


Prometheus Laboratories Inc. to Acquire GlaxoSmithKline (GSK) Bowel Drug
November 7, 2007


Affymax® Announces Hematide™ Successfully Restores Hemoglobin in Patients with Pure Red Cell Aplasia (PRCA)
November 5, 2007


Relypsa formed with $33 Million Series A Funding to discover and develop polymeric drugs.
October 29, 2007


GlaxoSmithKline (GSK) and Tolerx, Inc. Form Collaboration Worth Up to $700 Million
October 23, 2007


Gary Shearman, Ph.D. Joins Board of Artisan Pharma, Inc.
October 23, 2007


Aspreva to be Acquired by Galenica For US$915 Million
October 17, 2007


Aureon Laboratories to Collaborate with UCSF on Research Study to Construct Predictive Models for GM-CSF Treatment Response in Patients with Prostate Cancer
October 15, 2007


Affymax Doses First Patient in the Phase 3 Clinical Program of Hematide™ to Treat Anemia in Chronic Renal Failure Patients
October 11, 2007


NxStage Medical Completes Acquisition of Medisystems
October 1, 2007


Spiration, Inc. Announces First Patient Enrollment in U.S. Pivotal Trial of Minimally Invasive Treatment for Severe Emphysema
September 26, 2007


ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
September 26, 2007


Pearl Therapeutics Raises $15.5 Million in Private Financing
September 6, 2007


ISTA Pharmaceuticals Completes $36.75 Million Private Financing
June 29, 2007


TransOral Pharmaceuticals, Inc. Changes Name to Transcept Pharmaceuticals, Inc.
June 22, 2007


BioRelix Announces $25.75 Million Series A
June 11, 2007


Auxilium Pharmaceuticals Announces Sale of Common Stock
June 8, 2007


Amgen to Acquire Ilypsa, a Private San Francisco Bay Area Biotechnology Company Focused on Kidney Disease Care
June 4, 2007


NxStage® Medical Announces Agreement to Acquire Medisystems Corporation and Certain Affiliated Entities
June 4, 2007


TIBCO to Acquire Spotfire
May 1, 2007


Intarcia Raises $50 Million in a Series BB Financing
March 19, 2007


New Leaf Venture Partners and TPG Growth Co-Lead $20 Million Series B Financing in ProteoGenix
March 14, 2007


TransOral Pharmaceuticals Raises $40 Million in Series D Financing
March 6, 2007


Adeza to Be Acquired by Cytyc for $24 Per Share
February 12, 2007


Cerexa to be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
December 14, 2006


Concert Pharmaceuticals Raises $48.5 Million in Series B Financing
November 30, 2006


Merck & Co., Inc. to Acquire Sirna Therapeutics, Inc.
October 30, 2006


VaxInnate Secures $40 Million Series C Financing
October 25, 2006


Barrier Therapeutics, Inc. to Raise $25 Million in Registered Direct Offering
September 15, 2006


Artisan Pharma, Inc. Raises $39 Million in a Series A Financing
September 2, 2006


New Leaf Venture Partners Announces $12 Million Financing in Tioga Pharmaceuticals
January 9, 2006


New Leaf Venture Partners Announces $8.5 Million Financing in TransOral Pharmaceuticals
October 28, 2005


New Leaf Venture Partners Announces $3.5 Million Financing in Direct Flow Medical
September 7, 2005


New Leaf Venture Partners Announces $8 Million Investment in Cerexa's $50 Million Financing; Investment is First from NLV Partners' Recently Announced Fund Dedicated to Healthcare Technologies
August 23, 2005